Targeted therapy in esophageal cancer

: Esophageal cancer consists of two distinct histological types, esophageal squamous cell-carcinoma (ESCC) and adenocarcinoma (EAC). carcinoma is a grave malignancy with regards to prognosis mortality. ESCC remains the dominant type worldwide, about 90 percent all cases worldwide. However, EAC now much more common in United States Western World, represents one fastest growing cancers there. Despite significant progress multimodality treatment options, overall poor, 5-year survival rates for all-comers are still below 20 percent. Although initially responds well systemic therapy, most patients recur eventually die from their disease. Therefore, new options urgently needed. The combination traditional therapy biologicals and/or targeted agents these options. Some already approved, while others currently undergoing clinical trials. These therapies have emerged as an important tool many different including cancer. Herein, we review recent literature ongoing trials therapies, discuss pathways. Currently, treated chemotherapies like taxanes (paclitaxel, docetaxel), platinums (carboplatin, cisplatin), anthracyclines (doxorubicin, epirubicin) or pyrimidine analogs (5-fluorouracil). Future strategies should be based on molecular features each patient’s individual tumor, include biologicals/targeted tailored specific findings.